Q1 FY2026 · ended Mar 31, 2026 · Revenue $23,170, -7.3% YoY · Filed May 14, 2026
Biorestorative Therapies, Inc. (BRTX) files with the SEC under industry code 8090, Services-Misc Health & Allied Services, NEC. In Q1 of fiscal 2026, the quarter ended Mar 31, 2026, it reported revenue of $23,170 and a net loss of $2.2 million.
Revenue
$23,170
-7.3% vs year-ago quarter
Net income
$-2.15M
+59.7% vs year-ago quarter
Operating cash flow
$-3.81M
-37.0% vs year-ago quarter
Free cash flow
$-2.49M
-5.7% vs year-ago quarter
EPS
$-0.12
+81.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
25.48M
+239.5% vs year-ago quarter
Net cash
$13.05M
Q3 FY2024
Operating margin
-3975.0%
TTM
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- BRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Melville, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1505497
- Former names
- Stem Cell Assurance, Inc. (until Aug 16, 2011)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $23,170 | $19,600 | $11,800 | $303,300 | $25,000 |
| Operating income | -$3.4M | -$3.8M | -$3.7M | -$3.3M | -$4.8M |
| Net income | -$2.2M | -$3.2M | -$3.0M | -$2.7M | -$5.3M |
| Diluted EPS | -$0.12 | -$0.33 | -$0.33 | -$0.30 | -$0.64 |
| Operating cash flow | -$3.8M | -$2.4M | -$2.9M | -$2.7M | -$2.8M |
| Free cash flow | — | -$2.5M | -$2.9M | -$2.7M | -$2.8M |
| Total assets | $4.6M | $4.1M | $5.6M | $8.5M | $10.3M |
| Total liabilities | — | — | — | $3.7M | $4.2M |
| Stockholders' equity | $3.0M | $356,744 | $2.2M | $4.8M | $6.1M |
| Cash and investments | $3.6M | $3.0M | $4.5M | $7.4M | $9.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 4, 2026 |
| 8-K/A |
Amended current report
Auditor change, Other events
|
Sep 10, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Auditor change, Officer or director change
|
Sep 2, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 25, 2026 | Aug 21, 2026 |
All 754 Biorestorative Therapies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.